Prognostic impact of perioperative CA-125 levels in patients with endometrial cancer.

Elevated CA-125 levels have been reported in some women with endometrial carcinoma. Current follow-up policy for these patients does not involve the use of tumor markers. CA-125 measurements were performed in 28 patients with a diagnosis of endometrial cancer, 14 clinically free of disease and 14 with known disease. Based on the sensitivity (0.64) and specificity (0.93) observed we constructed a model to estimate the predictive value of the assay as a marker in the follow-up of patients who have completed treatment. This model would involve a CA-125 assay every six months for five years in 100 patients with stage I and II disease. Despite the high statistical correlation between the clinical status of the patient and the CA-125 value observed in our study, the positive predictive value would be approximately 24% in such a follow-up protocol where a low prevalence of recurrent malignancy is expected.

Download Full-text

Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer

Human Pathology ◽

10.1016/j.humpath.2010.05.006 ◽

2010 ◽

Vol 41 (11) ◽

pp. 1516-1529 ◽

Cited By ~ 41

Author(s):

Mitsuhiro Nakamura ◽

Satoru Kyo ◽

Bo Zhang ◽

Xiuzhi Zhang ◽

Yasunari Mizumoto ◽

...

Keyword(s):

Endometrial Cancer ◽

Prognostic Impact ◽

Cell Marker ◽

Cd133 Expression ◽

Tumor Initiating Cell

Download Full-text

Preoperative CA-125 in low-grade endometrial cancer: risk stratification and implications for treatment

Journal of Gynecologic Oncology ◽

10.3802/jgo.2019.30.e92 ◽

2019 ◽

Vol 30 (5) ◽

Cited By ~ 1

Author(s):

Janice S. Kwon

Keyword(s):

Endometrial Cancer ◽

Cancer Risk ◽

Risk Stratification ◽

Ca 125 ◽

Low Grade ◽

Endometrial Cancer Risk

Download Full-text

Abstract LB-299: Prognostic impact of EMT (epithelial-mesenchymal-transition) related protein expression in endometrial cancer

10.1158/1538-7445.am2012-lb-299 ◽

2012 ◽

Author(s):

Yoshimichi Tanaka

Keyword(s):

Endometrial Cancer ◽

Protein Expression ◽

Epithelial Mesenchymal Transition ◽

Prognostic Impact ◽

Related Protein ◽

Mesenchymal Transition

Download Full-text

Weekly ixabepilone with or without concurrent bevacizumab in the treatment of recurrent endometrial cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e15526 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e15526-e15526 ◽

Cited By ~ 1

Author(s):

Dana Marie Roque ◽

Elena Ratner ◽

Dan-Arin Silasi ◽

Masoud Azodi ◽

Peter E. Schwartz ◽

...

Keyword(s):

Endometrial Cancer ◽

Ca 125 ◽

Platinum Resistant ◽

Phase Ii Studies ◽

Disease Stabilization ◽

Long Term Follow Up ◽

Institutional Experience ◽

Recurrent Endometrial Cancer ◽

First Recurrence ◽

Dosing Strategy

e15526 Background: Ixabepilone for endometrial cancer has only been evaluated in phase II studies administered at 30-40 mg/m2 q21 days (GOG 129P, GOG 86P). The objective of this study is to describe the institutional experience using a weekly dosing strategy of ixabepilone ± bevacizumab in the treatment of paclitaxel/platinum-resistant recurrent endometrial cancer. Methods: Patients who received weekly ixabepilone (16-20 mg/m2 on days 1, 8, 15 of a 28-day cycle) ± bevacizumab (10 mg/kg on days 1, 15 of a 28-day cycle) off-protocol were identified retrospectively. Results: Thirteen patients were included. Demographic/disease characteristics are provided in Table 1. Median time to first recurrence was 15.9 months (IQR: 9.5-21.66). Patients received a mean of 4.8 ± 1.9 cycles of ixabepilone; treatment is ongoing in 4 patients. A total of 46% of patients demonstrated either a partial response (PR, 8%) or disease stabilization (SD, 38%). PR/SD was associated with a mean decline in CA-125 of 56%. Approximately 50% of patients received concurrent bevacizumab. Of patients who did not receive concurrent bevacizumab, 83% experienced progression and 17% demonstrated SD. Median survival after ixabepilone initiation was 12.7 and 6.9 months in patients treated with and without concurrent bevacizumab, respectively (HR 0.42 [0.09-1.98]). Grade 1/2 hematologic (thrombocytopenia, 15.4%) and gastrointestinal toxicities (emesis/constipation, 7.7%) were observed infrequently. Median overall survival of this cohort was 2.88 years. Conclusions: Ixabepilone shows encouraging activity and promising durability in patients with heavily pre-treated paclitaxel/platinum-resistant recurrent endometrial cancer. Weekly dosing at 16-20mg/m2 on days 1, 8, and 15 ± bevacizumab is well-tolerated. Additional investigation of this regimen and long-term follow-up is warranted. [Table: see text]

Download Full-text

Clinical Significance of Serum Interleukin-31 and Interleukin-33 Levels in Patients of Endometrial Cancer: A Case Control Study

Disease Markers ◽

10.1155/2016/9262919 ◽

2016 ◽

Vol 2016 ◽

pp. 1-7 ◽

Cited By ~ 15

Author(s):

Xi Zeng ◽

Zhu Zhang ◽

Qian-Qian Gao ◽

Yan-Yun Wang ◽

Xiu-Zhang Yu ◽

...

Keyword(s):

Endometrial Cancer ◽

Tumor Markers ◽

Sensitivity And Specificity ◽

Serum Levels ◽

Ca 125 ◽

Depth Of Invasion ◽

Healthy Controls ◽

Clinical Markers ◽

Interleukin 33 ◽

Tumor Stages

Aims. Previous evidence has proved that interleukin-31 (IL-31) and interleukin-33 (IL-33) can be potential markers in some cancers’ formulation. We aimed to determine the potential role of IL-31 and IL-33 in prognosis of endometrial cancer patients.Methods. Serum samples were collected from 160 patients with endometrial cancer and 160 healthy controls. The ELISA kits (Raybio® Systems) specific for human IL-31 and human IL-33 were used. Serum levels of tumor markers (CEA, CA-125, and CA19-9) were measured by chemiluminescence immunoassay. A two-sidePvalue < 0.05 was indicated to be significant.Results. Serum levels of IL-31 and IL-33 in patients were significantly elevated compared to those of healthy controls. The interleukin levels were also related to clinical characteristics, including tumor stages, depth of invasion, and existence of node metastases and distant metastases. The sensitivity and specificity of IL-31 and IL-33 were higher than the counterparts of tumor markers, both separately and in combination of IL-31, IL-33, and the clinical markers.Conclusions. This report is the first one mentioning the possible association between serum IL-31 and IL-33 and endometrial cancer. With their sensitivity and specificity, the interleukins may be useful biomarkers for endometrial cancer’s prognosis.

Download Full-text

HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases

Disease Markers ◽

10.1155/2017/9792756 ◽

2017 ◽

Vol 2017 ◽

pp. 1-13 ◽

Cited By ~ 5

Author(s):

Anita Chudecka-Głaz ◽

Aneta Cymbaluk-Płoska ◽

Aleksandra Strojna ◽

Janusz Menkiszak

Keyword(s):

Endometrial Cancer ◽

Gene Mutation ◽

Uterine Cancer ◽

Brca1 Gene ◽

Prophylactic Surgery ◽

Ca 125 ◽

Fallopian Tube Cancer ◽

Brca1 Gene Mutation ◽

Gynecological Diseases ◽

Diagnostic Usefulness

Objective. We assess the behavior of serum concentrations of HE4 marker in female carriers of BRCA1 and assess the diagnostic usefulness of HE4 in ovarian and endometrial cancer.Methods. A total of 619 women with BRCA1 gene mutation, ovarian, endometrial, metastatic, other gynecological cancers, or benign gynecological diseases were included. Intergroup comparative analyses were carried out, the BRCA1 gene carriers subgroup was subjected to detailed analysis, and ROC curves were determined for the assessment of diagnostic usefulness of HE4 in ovarian and endometrial cancer.Results. Statistically lower serum HE4 and CA 125 levels were observed in BRCA1 gene mutation premenopausal carriers. Occult ovarian/fallopian tube cancer was found 3.6%. Each of those patients was characterized by slightly elevated levels of either CA 125 (63.9 and 39.4 U/mL) or HE4 (79 pmol/L). The ROC-AUC curves were 0.892 and 0.894 for diagnostic usefulness of ovarian cancer and 0.865 for differentiation of endometrial cancer from endometrial polyps.Conclusions. Patients with BRCA1 gene mutations have relatively low serum HE4 levels. Even the slightest elevation in HE4 or CA 125 levels in female BRCA1 carriers undergoing prophylactic surgery should significantly increase oncological alertness. The HE4 marker is valuable in ovarian and uterine cancer diagnosis.

Download Full-text

Predicting Model of Lymph Node Metastasis Using Preoperative Tumor Grade, Transvaginal Ultrasound, and Serum CA-125 Level in Patients With Endometrial Cancer

International Journal of Gynecological Cancer ◽

10.1097/igc.0000000000000820 ◽

2016 ◽

Vol 26 (9) ◽

pp. 1630-1635 ◽

Cited By ~ 5

Author(s):

Jisun Lee ◽

Tae-Wook Kong ◽

Jiheum Paek ◽

Suk-Joon Chang ◽

Hee-Sug Ryu

Keyword(s):

Endometrial Cancer ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Myometrial Invasion ◽

Tumor Grade ◽

Ca 125 ◽

Transvaginal Sonography ◽

Endometrioid Adenocarcinoma ◽

Predicting Model ◽

Node Metastasis

ObjectiveThe purpose of this study was to evaluate the predicting model for lymph node metastasis using preoperative tumor grade, transvaginal sonography (TVS), and serum cancer antigen 125 (CA-125) level in patients with endometrial cancer.Materials and MethodsBetween January 2000 and February 2013, we identified 172 consecutive patients with surgically staged endometrial cancer. Transvaginal sonography was performed by an expert gynecologic radiologist in all patients. All patients had complete staging surgery including total hysterectomy with bilateral pelvic and para-aortic lymphadenectomy and were staged according to the 2009 International Federation of Gynecology and Obstetrics classification. Various clinicopathologic data were obtained from medical records and were retrospectively analyzed.ResultsOf 172 patients, 138 patients presented with stage I (118 IA and 20 IB), 12 had stage II, 18 had stage III (2 IIIA, 1 IIIB, 8 IIIC1, and 7 IIIC2), and 2 had stage IV diseases. Most patients had endometrioid adenocarcinoma (88.4%), and others (12.6%) had nonendometrioid histology. Eighteen patients (10.5%) were found to have lymph node metastasis. Deep myometrial invasion on preoperative TVS (≥50%), high serum CA-125 level (≥ 35 IU/mL), preoperative grade 2 or 3 tumors were significant preoperative factors predicting lymph node metastasis. There was no significant association between preoperative histology and lymph node metastasis. We calculated the simple model predicting lymph node metastasis based on preoperative tumor grade, TVS findings, and CA-125 level using logistic regression analysis. The sensitivity and specificity of this model were 94% and 57%, respectively (area under the curve, 0.84; 95% confidence interval [CI], 0.74–0.93; P < 0.01).ConclusionsPreoperative tumor grade, myometrial invasion on preoperative TVS, and CA-125 can accurately predict lymph node metastasis in patients with endometrial cancer. The current study suggests the possibility that TVS could be positively used for preoperative evaluation strategy in the low-resource countries instead of expensive imaging modalities such as magnetic resonance imaging or positron emission tomography–computed tomography.

Download Full-text